CITIC Capital increases capital by 2.92 billion yuan to take control of Ha drug

Pharmaceutical network January 11th, after 3 months, the drug group mixed reform has made substantial progressRecently, Harbin Municipal People's Government and CITIC Capital cooperation signing ceremony was held in Kazakhstan Pharmaceutical GroupCITIC Capital has increased its capital to the Ha Pharmaceutical Group by 2.92 billion yuan to take control of Ha Pharmaceutical Group and will set up a 20 billion yuan investment fund in Harbin City, Heilongjiang Citic Capital Pharmaceutical Industry Equity Investment Fundthe main body of this capital increase is Ha Pharmaceutical Group Co., Ltd., for the establishment of ASino-foreign joint venturein accordance with the lawIndustry insiders said that the CITIC Capital to the Pharmaceutical Group to increase capital, the establishment of 20 billion yuan pharmaceutical development fund in Harbin, Harbin to deepen the reform of state-owned enterprises is an important strategic initiative, is conducive to the overall research and development production and manufacturing capacity of the Kazakhstan Pharmaceutical Group to improve, to promote the pharmaceutical group to become better, bigger and stronger, will play an important role in promoting the development of the pharmaceutical industry in Harbin Cityit is understood that the pharmaceutical group was established in 2005, registered capital of 3.7 billion yuanAmong them, Harbin State-owned Assets Supervision and Administration Co., Ltdcontributed 1.665 billion yuan, holding 45%, CITIC Capital Iceland Investment Co., Ltd("CIC Iceland") and Huaping Iceland Investment Co., Ltd(hereinafter referred to as "Huaping Iceland") each contributed 833 million yuan, holding 22.5 percent, respectively, Harbin State-owned Enterprise Restructuring Management Consultants Co., Ltd(hereinafter referred to as "So-owned Enterprise Reorganization Company") contributed 370 million yuan, holding 10%After the capital increase of CITIC Capital, the registered capital of Hapharma Group will be increased from 3.7 billion yuan to 5.2 billion yuan (the capital increase exceeds the subscription registered capital portion of the capital reserve of Hapharmaceutical Group), the equity structure will be changed to: 32.02 percent of the sasac holdings in Harbin City; Ha Pharmaceutical Group and its subsidiary Ha Pharmaceutical stake and the actual controller of The People's Tongtai will be changed from Harbin SASAC to CITIC Capitalit is understood that this involved control of the two listed companies, the matter of the mixed reform, it is by its actual controller Harbin SASAC to promoteHa Pharmaceuticals, People's Anda i have been suspended from trading since the opening of the market on September 28, 2017After a three-month period, the mix-up was finalizedat present, Ha Pharmaceutical Group in the "China Pharmaceutical Industry Top 100 Enterprises" ranked 36th, in the top 100 enterprises in the second echelon of the middleThrough this capital increase, HaPharmaceutical Group will use the funds raised to start and continue to promote the project spevened by CITIC Capital for the hassle group, and strive to complete the existing investment and landing of CITIC Capital Reserve within 3-5 years, and promote the transformation and upgrading of hapharmaceutical group, rapid developmentAccording to the 2016 ranking comparable caliber calculation, in the next 3-5 years will be ranked in the "China Pharmaceutical Industry Top 100" top 10 enterprises, become the first echelon of enterprisesWith the follow-up and landing of CITIC Capital's follow-up reserve project, it will help Harpharma Group to maintain its rapiddevelopment momentum, further consolidate and move forward in the industry rankings, and reshape the strong wind of hapharmaceutical groupHeilongjiang CITIC CapitalIndustrial Equity Investment Fund has been set up, is in the fund raising and in place stage, the fund size of 20 billion yuanThe first phase of the funds expected to be about 3 billion yuan, will mainly participate in the mixed reform of the Kazakhstan Pharmaceutical Group, the second phase of the proposed fund-raising of 7 billion yuan, will mainly focus on the medical industry merger and acquisition integration around the pharmaceutical industry, the third phase of the proposed fund-raising 10 billion yuan for Heilongjiang Province pharmaceutical industry investmentInvest in pharmaceutical, medical and health industries in Harbin and Heilongjiang province as a whole, and promote the development and upgrading of local related industries.